LeadArt Biotechnologies is a pioneering biotechnology company, dedicated to advancing drug discovery through its cutting-edge chemical proteomics technology. As the first biotech company in China with this expertise, LeadArt holds a unique position within the global market. Backed by its parent company, Ningbo LeadArt Biotechnology, LeadArt boasts a strong foundation and a proven track record in biotechnology automation equipment development.

With state-of-the-art biotechnology and advanced automation technology, LeadArt is actively working towards creating the world's largest live cell target-probe database. By expanding the drug target space and accelerating drug discovery, LeadArt is revolutionizing the field and shaping the future of medicine. Under the leadership of Dr.

Feng Ni, a renowned expert in chemoproteomics and medicinal chemistry, and Dr. Yufeng Zhao, a distinguished member of the Chinese Academy of Sciences, LeadArt has assembled a stellar team of industry experts. Together, they bring decades of experience and knowledge in chemical biology research, drug discovery, and development.

In its impressive history, LeadArt has achieved notable milestones, including establishing research and development centers, securing major financing, and forming strategic partnerships with universities, research institutes, and medical companies. LeadArt's commitment to innovation and collaboration has cemented its position as a leading player in the field of chemoproteomics and automation. Copyright@2022 LeadArt Biotechnologies, Inc.

All rights reserved